Saturday, July 11, 2026

Drug profile · INN

novobiocin sodium

novobiocin sodium (ALBAMYCIN) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — novobiocin sodium
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

novobiocin sodium (ALBAMYCIN) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN novobiocin sodium
Brand ALBAMYCIN
Mechanism DNA gyrase inhibitor
Target DNA gyrase
Route ORAL
Formulation CAPSULE

Mechanism of action

DNA gyrase inhibitor

Primary target: DNA gyrase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. cinoxacin Bacterial DNA gyrase inhibitor
  2. ciprofloxacin Bacterial DNA gyrase inhibitor
  3. ciprofloxacin hydrochloride Bacterial DNA gyrase inhibitor
  4. levofloxacin Antiinfectives for systemic use (J01)
  5. moxifloxacin hydrochloride Bacterial DNA gyrase inhibitor
  6. ofloxacin Bacterial DNA gyrase inhibitor

Frequently asked questions

What is novobiocin sodium?

novobiocin sodium (ALBAMYCIN) is a dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for novobiocin sodium?

ALBAMYCIN is a marketed brand name for novobiocin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of novobiocin sodium?

novobiocin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.